Endoscopy 2011; 43(8): 702-708
DOI: 10.1055/s-0030-1256226
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Outcomes of endoscopic transpapillary gallbladder stenting for symptomatic gallbladder diseases: a multicenter prospective follow-up study[*]

T.  H.  Lee1 , D.  H.  Park2 , S.  S.  Lee2 , D.  W.  Seo2 , S.  H.  Park1 , S.  K.  Lee2 , M.  H.  Kim2 , S.  J.  Kim1
  • 1Department of Internal Medicine, Soon chun Hyang University College of Medicine, Cheonan Hospital, Cheonan, Republic of Korea
  • 2Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Further Information

Publication History

submitted 24 July 2010

accepted after revision 8 December 2010

Publication Date:
21 March 2011 (online)

Background and study aims: Endoscopic transpapillary gallbladder drainage for symptomatic gallbladder disease is a safe and effective bridge therapy in patients at high risk for surgery or who have terminal liver disease and are awaiting transplantation. However, there are few reports on long-term results in terms of stent patency and clinical course. Our study was designed to investigate the long-term patency and clinical course after endoscopic transpapillary gallbladder stenting (ETGS) in patients with symptomatic gallbladder disease.

Patients and methods: A total of 29 patients who were unsuitable for cholecystectomy underwent ETGS from June 2006 to March 2010 using a 7-Fr double-pigtail stent between the gallbladder and the duodenum. Their clinical progress, adverse events, and stent patency after ETGS were recorded prospectively in two tertiary referral centers.

Results: Technically, ETGS was successful in 23 (79.3 %) of the 29 patients. The mean procedure time was 22.4 ± 11.5 min. Postprocedure adverse events were mild pancreatitis (8.7 %) and cholestasis (8.7 %), all of which resolved with conservative management. During the follow-up period (median 586 days, range 11 – 1403 days), 20 patients were analyzed as per protocol, and scheduled follow-up was performed. Late adverse events developed in four patients (20 %), including distal migration (n = 2), cholangitis (n = 1), and recurrent biliary pain (n = 1). The remaining 16 patients were followed for more than 12 months (nine patients were followed for more than 24 months). Median stent patency was 760 days, as determined by the Kaplan-Meier method.

Conclusions: As a primary therapy, ETGS is technically feasible and effective in patients who are unsuitable for cholecystectomy. ETGS may also provide long-term stent patency without the need for scheduled stent exchanges.

1 Part of this study was presented in a topic forum at Digestive Disease Week, 1 – 5 May 2010 (New Orleans, Louisiana, USA).

References

1 Part of this study was presented in a topic forum at Digestive Disease Week, 1 – 5 May 2010 (New Orleans, Louisiana, USA).

D. H. ParkMD 

Division of Gastroenterology
Department of Internal Medicine
University of Ulsan College of Medicine
Asan Medical Center

388-1 Pungnap-2dong
Songpagu
Seoul
Republic of Korea

Fax: +82-2-485-5782

Email: dhpark@amc.seoul.krj991008@hanmail.net

    >